Anticoagulants Market Size To Reach $60.4 Billion By 2030

Anticoagulants Market Growth & Trends

The global anticoagulants market is anticipated to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 8.7% during the forecast period of 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

 Request a free sample copy or view report summary: Anticoagulants Market Report

Anticoagulants Market Report Highlights

• Novel oral anticoagulants (NOACs) dominated the drug category segment in 2023 owing to their ease of use and reduced need for monitoring, contributing to better adherence to treatment plans

• The Heparin and Low Molecular Weight Heparin (LMWH) segment is expected to grow at the fastest CAGR over the forecast period.

• The oral segment held the largest market share in 2023 and is expected to witness fastest growth over the forecast period.

• Sedentary lifestyle, increasing incidence of smoking, and rising air pollution are contributing to the growing prevalence of cardiovascular diseases

• Atrial fibrillation/myocardial infarction (Heart attack) dominated the application segment in 2023 owing to rising importance of monitoring and managing arrhythmia

• North America dominated the market owing to factors such as advanced healthcare infrastructure, favorable regulatory environment and rising public awareness of anticoagulant therapy

• In February 2022, FDA granted Bayer AG's anticoagulant Asundexian (BAY2433334) Fast-Track designation. The oral factor Xla inhibitor is currently undergoing phase 2 trials for the potential prevention of secondary thrombosis in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or more recently myocardial infarction.

Anticoagulants Market Segmentation

Grand View Research has segmented the anticoagulants market based on drug category, route of administration, application, and region:

Anticoagulants Drug Category Outlook (Revenue, USD Million; 2018 - 2030)

• Novel oral anticoagulants (NOACs)

  • Eliquis

  • Xarelto

  • Savaysa & Lixiana

  • Pradaxa

• Heparin and Low Molecular Weight Heparin (LMWH)

• Vitamin k Antagonist

• Direct thrombin inhibitors

• Others

Anticoagulants Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

• Oral anticoagulants

• Injectable anticoagulants

Anticoagulants Application Outlook (Revenue, USD Million; 2018 - 2030)

• Atrial fibrillation/myocardial infarction (Heart attack)

• Deep Vein Thrombosis (DVT)

• Pulmonary embolism

• Others

Anticoagulants Region Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Anticoagulants Market

• Aspen Holdings

• Pfizer Inc.

• Bristol-Myers Squibb Company

• GSK plc

• Sanofi

• Bayer AG

• Boehringer Ingelheim International GmbH

• DAIICHI SANKYO COMPANY, LIMITED

• Johnson & Johnson Services, Inc.

• Eisai Co., Ltd.